Is a
Patent attributes
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Date of Patent
November 8, 2022
Patent Application Number
16885767
Date Filed
May 28, 2020
Patent Citations
...
Patent Primary Examiner
Described herein are methods of treating non-metastatic castrate-resistant prostate cancer using an approved drug product comprising apalutamide, enzalutamide or darolutamide. Also described here are drug products containing apalutamide enzalutamide or darolutamide, and methods of selling or offering for sale an anti-androgen drug product.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
